Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The consolidation of Torii Pharmaceutical, the transfer of the JT pharmaceutical business and the edaravone business, the expanded prescribing of QUVIVIQ, edaravone sales in North America, cefiderocol sales in Europe and the United States, increased royalty income related to ViiV's HIV franchise, the share of profit from investments accounted for using the equity method following ViiV's transition to an equity-method associate, and the recognition of deferred tax assets in connection with the transfer of the edaravone business.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥163,310 million (YoY +63.7%) |
| Operating profit | ¥66,911 million (YoY +90.6%) |
| Ordinary income | ¥73,736 million (YoY +59.2%) |
| Profit attributable to owners of the parent | ¥97,696 million (YoY +148.2%) |
| Net income per share | ¥114.81 |
| Equity ratio | End of the current fiscal period 66.7 / End of previous period 65.3 |
| Total assets | ¥2,655,057 million |
| Net assets | ¥1,772,764 million |
| Cash flows from operating activities | ¥43,109 million |
| Cash flows from investing activities | ¥-423,731 million |
| Cash flows from financing activities | ¥-34,138 million |
| Cash and cash equivalents at end of period | ¥298,937 million |
| Full-year earnings forecast | Revenue ¥700,000 million (YoY +40.1%) / Operating profit ¥220,000 million (YoY +29.2%) / Pretax profit ¥220,000 million (YoY -9.3%) / Profit for the period attributable to owners of the parent ¥210,000 million (YoY +0.4%) |
| Revision to Earnings Forecast | Not disclosed → Not disclosed |
| Annual Dividend Forecast | ¥71 → ¥76（+7.0%） |
| Depreciation and amortization | ¥20,880 million (depreciation and amortization) |
| Breakdown of extraordinary income (loss) | The breakdown of extraordinary income and loss is Not disclosed. For reference, gains on bargain purchase of ¥48,970 million and ¥89 million were recorded in other income. |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Yes (retrospective restatement of prior-period figures following the finalisation of provisional accounting treatment for a business combination) |
| Changes in the scope of consolidation | Additions: 2 companies (RADIANCE NEWCO, LLC and 1 other company). Exclusions: Not disclosed. There were no other material changes. |
| Material subsequent events | On 1 July 2026, an absorption-type merger was carried out with Shionogi Inc. as the surviving company and RADIANCE NEWCO, LLC as the absorbed company. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for analysts) |
| Issued Shares at Period-End | 889,632,195 Shares |
| Treasury Shares at Period-End | 38,656,995 Shares |
| Factors Behind Changes in Business Performance | The consolidation of Torii Pharmaceutical, the transfer of the JT pharmaceutical business and the edaravone business, the expanded prescribing of QUVIVIQ, edaravone sales in North America, cefiderocol sales in Europe and the United States, increased royalty income related to ViiV's HIV franchise, the share of profit from investments accounted for using the equity method following ViiV's transition to an equity-method associate, and the recognition of deferred tax assets in connection with the transfer of the edaravone business. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company recorded product sales following the consolidation of Torii Pharmaceutical and the transfer of the JT pharmaceutical business and the edaravone business, as well as benefiting from the expanded prescribing of QUVIVIQ, edaravone sales in North America, cefiderocol sales in Europe and the United States, and increased royalty income related to ViiV's HIV franchise. Other factors contributing to the increase in profit included the share of profit from investments accounted for using the equity method following ViiV's transition to an equity-method associate, and the recognition of deferred tax assets in connection with the transfer of the edaravone business.